|1.||Kukreja, Rakesh C: 19 articles (03/2015 - 01/2005)|
|2.||Kloner, Robert A: 13 articles (06/2013 - 07/2003)|
|3.||Das, Anindita: 11 articles (03/2015 - 04/2005)|
|4.||Salloum, Fadi N: 10 articles (03/2015 - 02/2007)|
|5.||Guazzi, Marco: 9 articles (01/2013 - 12/2004)|
|6.||Xi, Lei: 7 articles (03/2015 - 04/2005)|
|7.||Dent, Paul: 5 articles (09/2015 - 10/2010)|
|8.||Steinhorn, Robin H: 5 articles (06/2015 - 02/2008)|
|9.||Farrow, Kathryn N: 5 articles (06/2015 - 02/2008)|
|10.||Hoke, Nicholas N: 5 articles (12/2014 - 09/2009)|
05/01/2013 - "Inhibition of phosphodiesterase-5 (PDE5) is a well-known mechanism for the effective treatment of erectile dysfunction (ED). "
10/01/2005 - "Conflicting information exists regarding the long-term efficacy of phosphodiesterase-5 (PDE5) inhibitor therapy for erectile dysfunction, particularly in regard to whether therapeutic resistance occurs. "
08/24/2006 - "Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones and their analogues, potentially useful for the treatment of erectile dysfunction, were synthesized and evaluated as inhibitors of phosphodiesterase 5 (PDE5). "
04/01/2002 - "In view of the clinical efficacy of phosphodiesterase-5 inhibitors, activation of sGC may provide an alternative means for enhancing the activity of neurally derived NO during sexual stimulation in the corpus cavernosum, representing a novel approach for the treatment of erectile dysfunction."
01/01/2012 - "The study's primary aim should be to investigate the efficacy of phosphodiesterase-5 inhibitors for treating male erectile dysfunction. "
06/01/2014 - "Inhibition of cGMP-specific phosphodiesterase 5 (PDE5) ameliorates pathological cardiac remodeling and has been gaining attention as a potential therapy for heart failure. "
07/12/2011 - "The multifaceted response to phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction includes improvement in pulmonary pressure and vasomotility, RV function and dimension, left ventricular relaxation and distensibility (structural changes and/or ventricular interdependence), and lung interstitial water metabolism (wedge pulmonary pressure decrease improving hydrostatic balance and right atrial pressure reduction facilitating lung lymphatic drainage). "
06/01/2003 - "In patients with heart failure, endothelial dysfunction is influenced by the phosphodiesterase-5 (PDE 5) inhibitor and exercise capacity might be improved. "
03/27/2013 - "Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preserved ejection fraction (HFPEF). "
11/01/2014 - "Prevention of right heart failure after left ventricular assist device implantation by phosphodiesterase 5 inhibitor."
|3.||Hypertension (High Blood Pressure)
01/01/2015 - "Phosphodiesterase-5 inhibitor therapy improved hemodynamics and functional class at six months in a cohort of patients with portopulmonary hypertension."
06/01/2009 - "In this study, a novel long-acting phosphodiesterase 5 inhibitor, PF-00489791, was evaluated in 133 patients with mild to moderate hypertension, randomized into 1 of 4 groups: placebo, 4 mg, 10 mg, and 20 mg titrated after 14 days of dosing to 40 mg. Study medication was administered once daily for 28 days. "
01/01/2015 - "Of 1385 patients screened, 25 patients with portopulmonary hypertension were identified, of whom 20 received a phosphodiesterase-5 inhibitor. "
01/01/2015 - "To evaluate the efficacy and safety of phosphodiesterase-5 inhibitor therapy in patients with portopulmonary hypertension. "
01/01/2015 - "Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension."
|4.||Pulmonary Hypertension (Ayerza Syndrome)
05/01/2009 - "cGMP-specific phosphodiesterase 5 (PDE5) inhibition has been shown to be effective in improving pulmonary haemodynamics in both animal models and clinic patients with pulmonary hypertension. "
07/01/2014 - "This study aimed to evaluate the therapeutic benefit of phosphodiesterase-5 (PDE-5) inhibitors in pulmonary hypertension secondary to ILD. "
05/01/2012 - "Phosphodiesterase-5 inhibitors are a promising method to treat pulmonary hypertension because of HFpEF. "
01/01/2010 - "Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy."
02/01/2004 - "This suggests that phosphodiesterase-5 inhibitors may potentially offer a therapeutic alternative in the management of acute pulmonary hypertension."
10/01/2009 - "The observed protective effects imply that phosphodiesterase-5 inhibition could be a novel therapeutic option in the protection against ischaemia-reperfusion injury in cardiac surgery."
03/01/2013 - "The cardiac and renal protective effects of phosphodiesterase-5 (PDE-5) inhibitors against ischemia-reperfusion injury have recently been demonstrated in animal studies. "
01/01/2014 - "Therefore, phosphodiesterase-5 can be explored as an important target to contain ischemia-reperfusion injury."
02/01/2012 - "Phosphodiesterase-5 inhibitor and rat lung ischemia-reperfusion injury."
01/01/2014 - "The present study investigates the neuroprotective effect of tadalafil, a selective phosphodiesterase-5 inhibitor, in a mouse model of ischemia-reperfusion injury. "
|4.||Phosphodiesterase 5 Inhibitors
|5.||5'-Guanylic Acid (GMP)
|1.||Prostatectomy (Retropubic Prostatectomy)
|4.||Transplantation (Transplant Recipients)
|5.||Drug Therapy (Chemotherapy)